Adrienne Graves
Directeur/Membre du Conseil chez NICOX SA
Fortune : 100 800 $ au 30/04/2024
Profil
Adrienne L.
Graves is the founder of Santen, Inc. (founded in 1995) and Glaucoma Research Foundation (founded in 2007).
She held the position of President & Chief Executive Officer at Santen, Inc. from 2002 to 2010.
Dr. Graves is also the founder of Ophthalmic Women Leaders.
Dr. Graves's current job(s) include being the Chairman at Retinal Degeneration Fund since 2022, a Director at Ocular Therapeutix, Inc. since 2023, a Director at Nicox Ophthalmics, Inc. since 2014, an Independent Director at Nicox SA since 2014, a Director at Implandata Ophthalmic Products GmbH since 2023, an Independent Director at Harrow, Inc. since 2024, an Independent Director at Surface Ophthalmics, Inc. since 2018, an Independent Director at Qlaris Bio, Inc. since 2019, a Director at Opus Genetics, Inc. since 2022, and a Member of The Association for Research in Vision & Ophthalmology.
Dr. Graves's former job(s) include being the Chairman at IVERIC bio, Inc. from 2018 to 2023, an Independent Director at Akorn, Inc. from 2012 to 2020, an Independent Director at TearLab Corporation, Inc. from 2005 to 2018, an Independent Director at Aerpio Therapeutics, Inc. from 2012 to 2017, the Director-International Ophthalmology at Alcon Laboratories, Inc. from 1986 to 1995, a Non-Executive Director at Oxurion NV from 2018 to 2023, an Independent Director at Encore Vision, Inc. from 2011 to 2017, a Director at Envisia Therapeutics, Inc. from 2014 to 2017, a Director at Aerpio Pharmaceuticals, Inc., an Independent Director at Greenbrook TMS, Inc. from 2018 to 2023, and a Director at TherOptix, Inc.Dr. Graves's education history includes an undergraduate degree from Brown University and a doctorate degree from the University of Michigan.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
OCULAR THERAPEUTIX INC
0,02% | 10/07/2023 | 24 000 ( 0,02% ) | 100 800 $ | 30/04/2024 |
GREENBROOK TMS, INC.
-.--% | 15/09/2023 | 0 ( -.--% ) | - $ | 30/04/2024 |
Postes actifs de Adrienne Graves
| Sociétés | Poste | Début |
|---|---|---|
| NICOX SA | Directeur/Membre du Conseil | 08/08/2014 |
| OCULAR THERAPEUTIX, INC. | Directeur/Membre du Conseil | 10/07/2023 |
| HARROW, INC. | Directeur/Membre du Conseil | 26/01/2024 |
| GREENBROOK TMS INC. | Directeur/Membre du Conseil | - |
| Retinal Degeneration Fund | Président | 21/07/2022 |
The Foundation Fighting Blindness, Inc.
 The Foundation Fighting Blindness, Inc. Miscellaneous Commercial ServicesCommercial Services The Foundation Fighting Blindness, Inc. provides preventions, treatments and cures for people affected by retinitis pigmentosa, macular degeneration and usher syndrome. The firm also provides provide information on retinal degenerative diseases to all who request it, in order to increase knowledge and awareness of these diseases. It has locations in Columbia, Denver, Libertyville, New York, Plano, Raleigh and Santa Monica. The company was founded on September 16, 1971 and is headquartered in Columbia, MD. | Directeur/Membre du Conseil | - |
Qlaris Bio, Inc.
 Qlaris Bio, Inc. BiotechnologyHealth Technology Qlaris Bio, Inc. operates as a biotechnology company. The company was founded by Thurein Htoo and Barbara Wirostko and is headquartered in Wellesley, MA. | Directeur/Membre du Conseil | 01/12/2019 |
Surface Ophthalmics, Inc.
 Surface Ophthalmics, Inc. BiotechnologyHealth Technology Surface Ophthalmics, Inc. operates as a biopharmaceutical company. It focuses on development and commercialization of innovative therapeutics. The firm’s current drug pipeline consists of three proprietary drug candidates. Surface topical eye drop drug candidates, SURF-100 and SURF-200, utilize a patented delivery vehicle. The company is founded by Mark L. Baum and it is headquartered in San Diego, CA. | Directeur/Membre du Conseil | 01/01/2018 |
Nicox Ophthalmics, Inc.
 Nicox Ophthalmics, Inc. Pharmaceuticals: MajorHealth Technology Nicox Ophthalmics, Inc. develops ocular diseases treatment products. It offers extensive pipeline such as a number of clinical and pre-clinical programs that principally target ocular allergy, ocular inflammation, and blepharitis. The company was founded by Thomas Cavanagh on December 21, 2007 and is headquartered in Fort Worth, TX. | Directeur/Membre du Conseil | 08/08/2014 |
| ░░░░ ░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░ ░░░░░░░ ░░ ░░░░░░░░ ░░░░░ ░░░░░░░░░░ ░░░░░░░ ░░░░░░░░░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | - |
| ░░░░░░ ░░░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | - |
Anciens postes connus de Adrienne Graves
| Sociétés | Poste | Fin |
|---|---|---|
| ░░░░░░░░░░ ░░░ ░░░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░ ░░░░ ░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░ ░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░ ░░░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░ ░░░░░░░░░░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | ░░░░░░░░░░ |
Formation de Adrienne Graves
| Brown University | Undergraduate Degree |
| University of Michigan | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 5 |
|---|---|
| OCULAR THERAPEUTIX, INC. | Health Technology |
| NICOX SA | Health Technology |
| OXURION NV | Health Technology |
| HARROW, INC. | Health Technology |
| GREENBROOK TMS INC. | Health Services |
| Entreprise privées | 31 |
|---|---|
Akorn, Inc.
 Akorn, Inc. Pharmaceuticals: MajorHealth Technology Akorn, Inc. engages in the development, manufacture, and marketing of generic and prescription pharmaceuticals, and animal and consumer health products. It manufactures and markets branded and generic products including ophthalmic, injectable, oral liquids, topical, inhalants, and nasal sprays. The company was founded in 1971 and is headquartered in Lake Forest, IL. | Health Technology |
TearLab Corporation, Inc.
 TearLab Corporation, Inc. Medical SpecialtiesHealth Technology TearLab Corporation, Inc. engages in the development and marketing of a tear testing platform. Its primary product, the TearLab Osmolarity System, enables eye care practitioners to test for highly sensitive and specific biomarkers using nanoliters of tear film at the point-of-care. It measures tear film osmolarity for the diagnosis of dry eye disease. The company was founded by Benjamin D. Sullivan in 1996 and is headquartered in Escondido, CA. | Health Technology |
Nicox Ophthalmics, Inc.
Nicox Ophthalmics, Inc. Pharmaceuticals: MajorHealth Technology Nicox Ophthalmics, Inc. develops ocular diseases treatment products. It offers extensive pipeline such as a number of clinical and pre-clinical programs that principally target ocular allergy, ocular inflammation, and blepharitis. The company was founded by Thomas Cavanagh on December 21, 2007 and is headquartered in Fort Worth, TX. | Health Technology |
Aerpio Therapeutics, Inc.
 Aerpio Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aerpio Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company focused on advancing innovative therapies for vascular diseases. The firm develops small molecules and monoclonal antibodies for the treatment of vascular disease and enhancement of wound healing. Its two lead programs include a tie-2 activator for diabetic macular edema and vascular leak, and a hypoxia-inducible factor 1-a stabilizer for wound healing and the treatment of inflammatory bowel disease. The company was founded by Joseph H. Gardner and Robert Shalwitz in 2011 and is headquartered in Cincinnati, OH. | Health Technology |
Alcon Laboratories, Inc.
 Alcon Laboratories, Inc. Medical SpecialtiesHealth Technology Alcon Laboratories, Inc. develops and manufactures ophthalmic pharmaceutical products. The firm offers over-the-counter eye care products, medical devices, equipment, ophthalmic drugs, surgical instruments, needles, and sutures for microsurgery and disposable drapes. The company was founded by Robert Alexander and William Conner in 1945 and is headquartered in Fort Worth, TX. | Health Technology |
The Foundation Fighting Blindness, Inc.
The Foundation Fighting Blindness, Inc. Miscellaneous Commercial ServicesCommercial Services The Foundation Fighting Blindness, Inc. provides preventions, treatments and cures for people affected by retinitis pigmentosa, macular degeneration and usher syndrome. The firm also provides provide information on retinal degenerative diseases to all who request it, in order to increase knowledge and awareness of these diseases. It has locations in Columbia, Denver, Libertyville, New York, Plano, Raleigh and Santa Monica. The company was founded on September 16, 1971 and is headquartered in Columbia, MD. | Commercial Services |
Santen, Inc.
 Santen, Inc. Medical SpecialtiesHealth Technology Part of Santen Pharmaceutical Co., Ltd., Santen, Inc. is a company that develops ophthalmic products. The company is based in Emeryville, CA. The company was founded in 1993 by Adrienne L. Graves. Tatsuya Kaihara has been the CEO of the company since 2017. | Health Technology |
| Pan-American Ophthalmological Foundation | |
The Association for Research in Vision & Ophthalmology
 The Association for Research in Vision & Ophthalmology Miscellaneous Commercial ServicesCommercial Services The Association for Research in Vision & Ophthalmology operates an association focused on research in vision and ophthalmology. The non-profit company is based in Rockville, MD. | Commercial Services |
American Academy of Ophthalmology, Inc.
 American Academy of Ophthalmology, Inc. Miscellaneous Commercial ServicesCommercial Services American Academy of Ophthalmology, Inc. is the world's largest association of eye physicians and surgeons. The non-profit company is based in San Francisco, CA, and has subsidiaries in the United States. The company advocates for patients and the public and set standards for ophthalmic education. The organization provides information about managing a practice, clinical pearls, and how to thrive in residency for young ophthalmologists. The company also offers an Outstanding Humanitarian Service Award and have committees that are essential to the establishment and implementation of the organization's mission and strategic goals. The Academy's website, EyeSmart, provides information on eye diseases, treatments, news, and tips for lifelong eye health. The company also has a faculty development program for their annual meeting and offer a program called Eyecelerator that advances eye care innovation by connecting creative entrepreneurs with mission-driven investors and access to markets. | Commercial Services |
American Glaucoma Society
 American Glaucoma Society Investment Trusts/Mutual FundsMiscellaneous The American Glaucoma Society supports glaucoma specialists and scientists through the advancement of education and research. | Miscellaneous |
Women in Ophthalmology, Inc.
 Women in Ophthalmology, Inc. Miscellaneous Commercial ServicesCommercial Services Women in Ophthalmology, Inc. provides support to ophthalmologists. It offers professional development, carrier advancement, and interactive networking to its members. The company is headquartered in Denver, CO. | Commercial Services |
| Ophthalmic Women Leaders | |
IVERIC bio, Inc.
 IVERIC bio, Inc. Pharmaceuticals: GenericHealth Technology IVERIC bio, Inc. operates as a biopharmaceutical company. The firm engages in discovering, developing and commercializing novel therapeutics to treat ophthalmic diseases, with a focus on age-related and orphan retinal diseases. Its product candidates include Zimura and Gene Therapy. The company was founded by David R. Guyer and Samir Chandrakant Patel on January 5, 2007 and is headquartered in Parsippany, NJ. | Health Technology |
| The American Society of Cataract & Refractive Surgery | |
| American Academy of Ophthalmology Foundation | |
Glaucoma Research Foundation
 Glaucoma Research Foundation Miscellaneous Commercial ServicesCommercial Services Glaucoma Research Foundation provides education services. The non-profit company is based in San Francisco, CA. The company was founded by Adrienne L. Graves. The CEO is Thomas M. Brunner. | Commercial Services |
Implandata Ophthalmic Products GmbH
 Implandata Ophthalmic Products GmbH Electronic Equipment/InstrumentsElectronic Technology Implandata Ophthalmic Products GmbH develops diagnosis tool for glaucoma therapy. Its technology Pro-IOP is an eye pressure measurement system consists of an implantable micro sensor, responsible for pressure sensing, an external hand held device, which is transferring energy to the micro sensor telemetrically and which is responsible for data read out and storage and a GSM module which can be connected with the hand held device for transfer of measurement data to a database, which can be accessed by the eye doctor in order to get information about the disease status of the patient. The company was founded by Max Georg Ostermeier and Stefan Meyer in January 2010 and is headquartered in Hannover, Germany. | Electronic Technology |
Encore Vision, Inc.
 Encore Vision, Inc. Medical/Nursing ServicesHealth Services Encore Vision, Inc. operates as an ophthalmology clinic. It offers EV06, an ophthalmic pharmaceutical solution in a conventional eye drop bottle, which includes its proprietary active pharmaceutical ingredient (API). The company is headquartered in Spokane, WA. | Health Services |
| American Society of Cataract & Refractive Surgery Foundation | |
| Himalayan Cataract Project | |
Envisia Therapeutics, Inc.
 Envisia Therapeutics, Inc. BiotechnologyHealth Technology Envisia Therapeutics, Inc. develops novel ocular therapies. It provides glaucoma drug therapies that include PRINT particle therapeutics to overcome biologic and chemical. The company was founded by 2013 is headquartered in Morrisville, NC. | Health Technology |
Aerpio Pharmaceuticals, Inc.
 Aerpio Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aerpio Pharmaceuticals Inc. is a biopharmaceutical company, which engages in the research and development of treatments for ocular diseases. The firm's product candidate is AKB-9778, a small molecule activator of the Tie2 pathway, which completed the Phase 2a clinical trial for the treatment of diabetic retinopathy. It also develops ARP-1536, a humanized monoclonal antibody that is in preclinical development stage for the treatment of diabetic vascular complications; and AKB-4924, a selective stabilizer of hypoxia-inducible factor-1 alpha, which has completed a single ascending dose clinical trial for the treatment of inflammatory bowel disease. The company was founded by Joseph H. Garder on November 16, 2007 and is headquartered in Cincinnati, OH. | Health Technology |
Surface Ophthalmics, Inc.
Surface Ophthalmics, Inc. BiotechnologyHealth Technology Surface Ophthalmics, Inc. operates as a biopharmaceutical company. It focuses on development and commercialization of innovative therapeutics. The firm’s current drug pipeline consists of three proprietary drug candidates. Surface topical eye drop drug candidates, SURF-100 and SURF-200, utilize a patented delivery vehicle. The company is founded by Mark L. Baum and it is headquartered in San Diego, CA. | Health Technology |
| Retinal Degeneration Fund | |
Qlaris Bio, Inc.
Qlaris Bio, Inc. BiotechnologyHealth Technology Qlaris Bio, Inc. operates as a biotechnology company. The company was founded by Thurein Htoo and Barbara Wirostko and is headquartered in Wellesley, MA. | Health Technology |
TherOptix, Inc.
 TherOptix, Inc. Electronic ComponentsElectronic Technology TherOptix, Inc. develops and manufactures drug-eluting contact lens. The company is headquartered in San Francisco, CA. | Electronic Technology |
NVasc, Inc.
 NVasc, Inc. Medical SpecialtiesHealth Technology NVasc, Inc. is an early-stage ophthalmology company founded in February 2019 and funded by Kairos Ventures in November 2019. The company is based in Atherton, CA. The company is focused on treating the leading causes of blindness through choroidal and retinal revascularization. The company is planning to manufacture NVB001 that can be used in toxicokinetic studies and in early clinical trials in humans. NVasc has acquired the research rights to growth factors (NVB001 and NVB002) that have been shown to encourage the growth of non-leaking new vessels in the retina and choroid in mouse models of ischemic eye diseases. | Health Technology |
| Retina Global | |
Opus Genetics, Inc.
 Opus Genetics, Inc. BiotechnologyHealth Technology Opus Genetics, Inc. is a gene therapy company that focuses on treating inherited retinal diseases. The company is based in Raleigh, NC, and leverages knowledge of the best science and the expertise of pioneers in ocular gene therapy to transparently drive transformative treatments to patients. The company has a unique model and purpose, and is backed by Foundation Fighting Blindness's venture arm, the RD Fund. Opus Genetics has wholly owned programs in numerous orphan retinal diseases, and its AAV-based gene therapy portfolio tackles some of the most neglected forms of inherited blindness while creating novel orphan manufacturing scale and efficiencies. The company was founded in 2021 by Benjamin R. Yerxa, Peter L. Ginsberg, Jason D. Menzo, Jean Bennett, Russell Kelley, Jean Bennett. Benjamin R. Yerxa has been the CEO since 2021. | Health Technology |
KeepYourSight Foundation
 KeepYourSight Foundation Investment Trusts/Mutual FundsMiscellaneous KeepYourSight Foundation provides e-health initiative in the fight against blindness. The company is headquartered in united States. | Miscellaneous |
